PRME240719C7500
- 0.10
- 0.000.00%
Prime Medicine Newsroom
US stocks closed | S&P and Nasdaq continue to hit new closing highs! Nvidia rose nearly 1% on the first day of its split.
The PHLX Semiconductor Index continued to break new highs, with Broadcom up 2.4%; the solar energy sector had the highest increase, with SinglePoint up more than 20%.
Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's Is How to Trade
Prime Medicine to Present at Upcoming Investor Conferences
PDF Version CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curati
GFS, PETS and CYTK Are Among After Hour Movers
URBN, SHLS and VSAT Are Among After Hour Movers
Cathie Wood Pulls the Trigger on These 2 'Strong Buy' Stocks
Prime Medicine Initiated at Buy by HC Wainwright & Co.
Prime Medicine Initiated at Buy by HC Wainwright & Co.
Prime Medicine (PRME.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $10.00.
Prime Medicine (PRME.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $10.00.
HC Wainwright & Co. Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Arthur He initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces Price Target of $10.
Alphabet Bought Shares of 2 Underperfomers -- Barron's
Ed Lin Alphabet stock has been surging, along with peers in the Magnificent Seven, and the company has increased stakes in some of its equity investments. The parent of YouTube and Google more than
Prime Medicine Raised to Buy From Neutral by Citigroup
Prime Medicine Raised to Buy From Neutral by Citigroup
Citi: Raised the Prime Medicine (PRME.US) rating from neutral to buy, with a target price of $10.00.
Citi: Raised the Prime Medicine (PRME.US) rating from neutral to buy, with a target price of $10.00.
Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target
Prime Medicine (PRME) has an average outperform rating and a price target range of $9 to $20, according to analysts polled by Capital IQ. Price: 7.07, Change: +0.31, Percent Change: +4.59
Shares of 'Meme Stocks' and High-short Interest Stocks Are Trading Higher Amid a Renewed Surge in the Space After Popular Retail Trader 'Roaring Kitty' Returned to Social Media.
Shares of 'Meme Stocks' and High-short Interest Stocks Are Trading Higher Amid a Renewed Surge in the Space After Popular Retail Trader 'Roaring Kitty' Returned to Social Media.
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
Onward and Upward: Prime Medicine's (PRME) Extended-Session Rally
In the extended session on Monday, the rally for Prime Medicine, Inc. (NASDAQ: PRME) stock persisted, with a noteworthy 5.61% surge after-hours, reaching $6.78. This surge further augmented the rise during regular trading hours, culminating at $6.42, marking a substantial 14.44% increase. The escalation in PRME stock value coincides with an imminent significant event. Executive ...
The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioScience
The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioSciences rose 16.60%-10.00% Novocure also rose 9.17%; Zent
Stocks With More Than 10% Short Interest - Finviz Screener
Prime Medicine Price Target Cut to $15.00/Share From $16.00 by JP Morgan
Prime Medicine Price Target Cut to $15.00/Share From $16.00 by JP Morgan
Prime Medicine Is Maintained at Overweight by JP Morgan
Prime Medicine Is Maintained at Overweight by JP Morgan